Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
复制标题
DOI：
10.1002/cncr.22918
复制
发表时间：
2007-09-15
期刊：
影响因子：
6.2
通讯作者：
Florenes, Vivi Ann
中科院分区：
文献类型：
--
作者：
Davidson, Ben;Skredel, Martina;Florenes, Vivi Ann
背景。作者最近报道了细胞周期蛋白 E 在使用基因表达阵列区分卵巢/原发性腹膜癌与恶性腹膜间皮瘤中的作用。在当前的研究中，他们分析了低分子量（LMW）形式的细胞周期蛋白E在卵巢癌、恶性间皮瘤和良性反应性积液中的表达。使用免疫印迹分析了 98 例积液（72 例卵巢癌、14 例恶性间皮瘤和 12 例反应性标本）中的细胞周期蛋白 E 蛋白表达。使用免疫组织化学进一步研究了 62 例卵巢癌积液的细胞周期蛋白 E 表达。分析卵巢癌中cyclin E表达与临床参数（包括化疗反应）之间的相关性。结果。在 72 例卵巢癌积液中的 54 例 (75%) 中发现了 LMW 形式的细胞周期蛋白 E，而在 14 例恶性间皮瘤积液中检测到 1 例 (7%)，在 12 例反应性积液中检测到 1 例 (8%) (P < .001)。它们在卵巢癌中的存在与较高比例的细胞周期蛋白 E 阳性细胞 (P = .001) 和免疫组织化学染色强度增加 (P < .001) 相关。 LMW 形式的细胞周期蛋白 E 的存在与较短的总生存期 (P = .021) 和无进展生存期 (P = .020) 相关。免疫组织化学显示较高比例的细胞周期蛋白 E 阳性细胞与较短的无进展生存期相关 (P = .026)。没有观察到与化疗反应相关。结论。免疫组织化学显示，LMW 形式的细胞周期蛋白 E 可将卵巢癌与良性和恶性间皮细胞区分开来，并与蛋白质表达增加相关。 LMW 细胞周期蛋白 E 形式的表达与化疗反应无关，尽管它可能是转移性卵巢癌患者侵袭性疾病的标志。
BACKGROUND. The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.METHODS. Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting. Sixty-two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry. The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.RESULTS. LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001). Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E-positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry. The presence of LMW forms of cyclin E was correlated with shorter overall survival (P = .021) and progression-free survival (P = .020). The presence of a higher percentage of cyclin E-positive cells using immunohistochemistry was correlated with shorter progression-free survival (P = .026). No association with chemotherapy response was observed.CONCLUSIONS. LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.